Truly a wonder substance, Japanese knotweed (JKW) offers exceptional antimicrobial activity. JKW is active against a wide range of stealth microbes.
It is a primary herbal antimicrobial. JKW is a very important general antimicrobial for Lyme, Mycoplasma, fibromyalgia, and viral infections. It also provides coverage against Bartonella, Mycoplasma, Candida, and viruses as well. JKW also offers antiviral, anti-Candida (yeast), and antifungal properties. It has been found to disrupt bacterial biofilms. JKW is a systemic antimicrobial that crosses the blood-brain barrier, and it is protective of the central nervous system. It’s also anti-inflammatory and supports immune function.
JKW is a “double duty” supplement that offers many profound benefits beyond antimicrobial properties. It is a particularly good source of resveratrol, the age-defying substance found in grapes and wine that everybody is talking about. But unlike grapes, JKW provides trans-resveratrol, the form most readily utilized by the body.
Resveratrol offers a list of benefits including potent antioxidant properties and support of normal heart function. It dilates blood vessels, improves blood flow, inhibits platelet aggregation (thins blood), and mildly lowers LDL cholesterol. Resveratrol is also protective of nerve tissue.
Beyond trans-resveratrol, the whole herb offers a spectrum of chemical substances that have medicinal value. Resveratrol and the whole herb support normal immune function and offer anti-inflammatory and anticancer properties. JKW has been used in traditional forms of Asian medicine for centuries and offers a high level of safety.
Suggested dosage: 200-800 mg Japanese knotweed (standardized to 50% trans-resveratrol) two to three times daily.
Side effects: Rare with low potential for toxicity. Caution is advised if also taking anticoagulants because resveratrol has blood-thinning properties. Avoid in pregnancy.
1. Su PW, Yang CH, Yang JF, Su PY, Chuang LY. Antibacterial Activities and Antibacterial Mechanism of Polygonum cuspidatum Extracts against Nosocomial Drug-Resistant Pathogens. Molecules. 2015;20(6):11119-11130.
2. Lin CJ, Lin HJ, Chen TH, et al. Polygonum cuspidatum and its active components inhibit replication of the influenza virus through toll-like receptor 9-induced interferon beta expression. PLoS One. 2015;10(2):e0117602.
3. Yiu CY, Chen SY, Yang TH, et al. Inhibition of Epstein-Barr virus lytic cycle by an ethyl acetate subfraction separated from Polygonum cuspidatum root and its major component, emodin. Molecules. 2014;19(1):1258-1272.
4. Liu Z, Wei F, Chen LJ, et al. In vitro and in vivo studies of the inhibitory effects of emodin isolated from Polygonum cuspidatum on Coxsakievirus B₄. Molecules. 2013;18(10):11842-11858.
5. Song JH, Kim SK, Chang KW, et al. In vitro inhibitory effects of Polygonum cuspidatum on bacterial viability and virulence factors of Streptococcus mutans and Streptococcus sobrinus. Arch Oral Biol. 2006;51(12):1131-1140.
6. Taraszkiewicz A, Fila G, Grinholc M, Nakonieczna J. Innovative strategies to overcome biofilm resistance. BioMed Res Int. 2013;2013:150653.
7. Wang HL, Gao JP, Han YL, et al. Comparative studies of polydatin and resveratrol on mutual transformation and antioxidative effect in vivo. Phytomedicine. 2015;22(5):553-559.
8. Kurita S, Kashiwaqi T, Ebisu T, Shimamura T, Ukeda H. Content of resveratrol and glycoside and its contribution to the antioxidative capacity of Polygonum cuspidatum (Itadori) harvested in Kochi. Biosci Biotechnol Biochem. 2014;78(3):499-502.
9. Kirino A, Takasuka Y, Nishi A, et al. Analysis and functionality of major polyphenolic components of Polygonum cuspidatum (itadori). J Nutr Sci Vitaminol (Tokyo). 2012;58(4):278-286.
10. Lin SP, Chu PM, Tsai SY, Wu MH, Hou YC. Pharmacokinetics and tissue distribution of resveratrol, emodin and their metabolites after intake of Polygonum cuspidatum in rats. J Ethnopharmacol. 2012;144(3):671-676.
11. Peng W, Qin R, Li X, Zhou H. Botany, phytochemistry, pharmacology, and potential application of Polygonum cuspidatum Sieb.et Zucc: a review. J Ethnopharmacol. 2013;148(3):729-745.
12. Han JH, Koh W, Lee HJ, et al. Analgesic and anti-inflammatory effects of ethyl acetate fraction of Polygonum cuspidatum in experimental animals. Immunopharmacol Immunotoxicol. 2012;34(2):191-195.
13. Ghanim H, Sia CL, Abuaysheh S, et al. An anti-inflammatory and reactive oxygen species suppressive effects of an extract of Polygonum cuspidatum containing resveratrol. J Clin Endocrinol Metab. 2010;95(9):E1-E8.
14. Xie HC, Han HP, Chen Z, He JP. A study on the effect of resveratrol on lipid metabolism in hyperlipidemic mice. Afr J Tradit Complement Altern Med. 2013;11(1):209-212.
15. Kakoti BB, Hernandez-Ontiveros DG, Kataki MS, Shah K, Pathak Y, Panguluri SK. Resveratrol and Omega-3 Fatty Acid: Its Implications in Cardiovascular Diseases. Front Cardiovasc Med. 2015;2:38.
16. Cheng L, Jin Z, Zhao R, Ren K, Deng C, Yu S. Resveratrol attenuates inflammation and oxidative stress induced by myocardial ischemia-reperfusion injury: role of Nrf2/ARE pathway. Int J Clin Exp Med. 2015;8(7):10420-10428.
17. Rabassa M, Zamora-Ros R, Urpi-Sarda M, Andres-Lacueva C. Resveratrol metabolite profiling in clinical nutrition research—from diet to uncovering disease risk biomarkers: epidemiological evidence. Ann N Y Acad Sci. 2015;1348(1):107-115.
18. Singh CK, Liu X, Ahmad N. Resveratrol, in its natural combination in whole grape, for health promotion and disease management. Ann N Y Acad Sci. 2015;1348(1):150-160.
19. Raj P, Zieroth S, Netticadan T. An overview of the efficacy of resveratrol in the management of ischemic heart disease. Ann N Y Acad Sci. 2015;1348(1):55-67.
20. Joshi MS, Williams D, Horlock D, et al. Role of mitochondrial dysfunction in hyperglycaemia-induced coronary microvascular dysfunction: Protective role of resveratrol. Diab Vasc Dis Res. 2015;12(3):208-216.
21. Zheng H, Guo H, Hong Y, Zheng F, Wang J. The effects of age and resveratrol on the hypoxic preconditioning protection against hypoxia-reperfusion injury: studies in rat hearts and human cardiomyocytes. Eur J Cardiothorac Surg. 2015;48(3):375-381.
22. Chong E, Chang SL, Hsiao YW, et al. Resveratrol, a red wine antioxidant, reduces atrial fibrillation susceptibility in the failing heart by PI3K/AKT/eNOS signaling pathway activation. Heart Rhythm. 2015;12(5):1046-1056.
23. Meng C, Liu JL, Du AL. Cardioprotective effect of resveratrol on atherogenic diet-fed rats. Int J Clin Exp Pathol. 2014;7(11):7899-7906.
Dolinsky VW, Dyck JR. Experimental studies of the molecular pathways regulated by exercise and resveratrol in heart, skeletal muscle and the vasculature. Molecules. 2014;19(9):14919-14947.
24. Liu Y, Ma W, Zhang P, He S, Huang D. Effect of resveratrol on blood pressure: a meta-analysis of randomized controlled trials. Clin Nutr. 2015;34(1):27-34.
25. Cong X, Li Y, Lu N, et al. Resveratrol attenuates the inflammatory reaction induced by ischemia/reperfusion in the rat heart. Mol Med Rep. 2014;9(6):2528-2532.
26. Mokni M, Hamlaoui S, Karkouch I, et al. Resveratrol Provides Cardioprotection after Ischemia/reperfusion Injury via Modulation of Antioxidant Enzyme Activities. Iran J Pharm Res. 2013;12(4):867-875.
27. Yang X, Li X, Ren J. From French Paradox to cancer treatment: anti-cancer activities and mechanisms of resveratrol. Anticancer Agents Med Chem. 2014;14(6):806-825.
28. Piotrowska H, Kucinska M, Murias M. Biological activity of piceatannol: leaving the shadow of resveratrol. Mutat Res. 2012;750(1):60-82.
29. Aluyen JK, Ton QN, Tran T, et al. Resveratrol: potential as anticancer agent. J Diet Suppl. 2012;9(1):45-56.
30. Pasinetti GM, Wang J, Ho L, Zhao W, Dubner L. Roles of resveratrol and other grape-derived polyphenols in Alzheimer’s disease prevention and treatment. Biochim Biophys Acta. 2015;1852(6):1202-1208.